EX-99.2O OTH FIN ST 4 exhibi99204q2010.htm exhibi99204q2010.htm
Exhibit 99.2O
 
Johnson & Johnson and Subsidiaries
                   
Condensed Consolidated Statement of Earnings
               
   
 
 
 
 
 
 
 
   
(Unaudited; in Millions Except Per Share Figures)
FOURTH QUARTER
   
2009
 
2008
 
Percent
       
Percent
     
Percent
 
Increase
   
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)
Sales to customers
 
 $         16,551
 
100.0
 
 $         15,182
 
100.0
 
9.0
Cost of products sold
 
             5,312
 
32.1
 
             4,372
 
28.8
 
21.5
Selling, marketing and administrative expenses
 
5,629
 
34.0
 
5,665
 
37.3
 
(0.6)
Research expense
 
2,213
 
13.4
 
2,108
 
13.9
 
5.0
In-process research & development (IPR&D)
 
                    -
 
                   -
 
                141
 
0.9
   
Interest (income)expense, net
 
81
 
0.5
 
17
 
0.1
   
Other (income)expense, net
 
(361)
 
(2.2)
 
(638)
 
(4.2)
   
Restructuring expense
 
             1,073
 
6.5
 
                    -
 
                    -
   
Earnings before provision for taxes on income
 
2,604
 
15.7
 
3,517
 
23.2
 
(26.0)
Provision for taxes on income
 
398
 
2.4
 
803
 
5.3
 
(50.4)
Net earnings
 
 $           2,206
 
13.3
 
 $           2,714
 
17.9
 
(18.7)
                     
Net earnings per share  (Diluted)
 
 $             0.79
     
 $             0.97
     
(18.6)
                     
Average shares outstanding  (Diluted)
 
2,796.5
     
2,801.6
       
                     
Effective tax rate
 
15.3
%
   
22.8
%
   
 
                     
Adjusted earnings before provision for taxes and net earnings (A)
             
     Earnings before provision for taxes on income
 $           3,404
 (1)
20.6
 
 $           3,279
 (2)
21.6
 
3.8
     Net earnings
 
 $           2,846
 (1)
17.2
 
 $           2,626
 (2)
17.3
 
8.4
     Net earnings per share  (Diluted)
 
 $             1.02
 (1)
   
 $             0.94
 (2)
   
8.5
     Effective tax rate
 
16.4
   
19.9
     
                     
 
(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of restructuring expense of $1,186 million ($1,073 million restructuring expense and $113 million related to restructuring included in cost of products sold), $852 million and $0.31 per share, respectively, and the exclusion of income from net litigation of $386 million, $212 million and $0.08 per share, respectively.
                       
(2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of IPR&D of $141 million with no tax benefit and $0.05 per share, respectively, and the exclusion of income from net litigation of $379 million, $229 million and $0.08 per share, respectively.
                       
 

 
 

 

Johnson & Johnson and Subsidiaries
                   
Condensed Consolidated Statement of Earnings
                   
         
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
 
TWELVE MONTHS
   
2009
 
2008
 
Percent
       
Percent
     
Percent
 
Increase
   
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)
Sales to customers
 
 $         61,897
 
100.0
 
 $         63,747
 
100.0
 
(2.9)
Cost of products sold
 
18,447
 
29.8
 
18,511
 
29.1
 
(0.3)
Selling, marketing and administrative expenses
 
19,801
 
32.0
 
21,490
 
33.7
 
(7.9)
Research expense
 
6,986
 
11.3
 
7,577
 
11.9
 
(7.8)
In-process research & development (IPR&D)
 
                    -
 
                   -
 
181
 
0.3
   
Interest (income)expense, net
 
361
 
0.6
 
74
 
0.1
   
Other (income)expense, net
 
(526)
 
(0.8)
 
(1,015)
 
(1.6)
 
 
Restructuring expense
 
             1,073
 
1.7
 
                    -
 
-
   
Earnings before provision for taxes on income
 
15,755
 
25.4
 
16,929
 
26.5
 
(6.9)
Provision for taxes on income
 
             3,489
 
5.6
 
             3,980
 
6.2
 
(12.3)
Net earnings
 
 $         12,266
 
19.8
 
 $         12,949
 
20.3
 
(5.3)
                     
Net earnings per share  (Diluted)
 
 $             4.40
     
 $             4.57
     
(3.7)
                     
Average shares outstanding  (Diluted)
 
2,789.1
     
2,835.6
       
                     
Effective tax rate
 
22.1
%
   
23.5
%
   
 
                     
Adjusted earnings before provision for taxes and net earnings (A)
               
     Earnings before provision for taxes on income
 $         16,555
 (1)
26.7
 
 $         16,731
 (2)
26.2
 
(1.1)
     Net earnings
 
 $         12,906
 (1)
20.9
 
 $         12,901
 (2)
20.2
 
-
     Net earnings per share  (Diluted)
 
 $             4.63
 (1)
   
 $             4.55
 (2)
   
1.8
     Effective tax rate
 
22.0
%    
22.9
 %       

(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of restructuring expense of $1,186 million ($1,073 million restructuring expense and $113 million related to restructuring included in cost of products sold), $852 million and $0.31 per share, respectively, and the exclusion of income from fourth quarter net litigation of $386 million, $212 million and $0.08 per share, respectively.

(2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of IPR&D of $181 million with no tax benefit and $0.06 per share, respectively, and the exclusion of income from fourth quarter net litigation of $379 million, $229 million and $0.08 per share, respectively.
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, they may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as business development activities (including IPR&D at acquisition or upon attainment of milestones and any extraordinary expenses), strategic developments (including restructuring and product line changes), significant litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, merger-related or other restructuring charges, or amortization of purchased intangibles, and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
 
 

 

Johnson & Johnson and Subsidiaries
               
Supplementary Sales Data
                 
                   
(Unaudited; Dollars in Millions)
FOURTH QUARTER*
         
Percent Change
 
2009
 
2008
 
Total
  Operations
Currency
Sales to customers by
                 
segment of business
                 
                   
Consumer
                 
    U.S.
 $  1,712
 
   1,655
 
   3.4
%
          3.4
 
            -
    International
     2,537
 
   2,200
 
 15.3
 
          6.5
 
        8.8
 
     4,249
 
   3,855
 
 10.2
 
          5.2
 
        5.0
                   
Pharmaceutical
                 
    U.S.
     3,338
 
   3,430
 
  (2.7)
 
         (2.7)
 
            -
    International
     2,655
 
   2,255
 
 17.7
 
          8.0
 
        9.7
 
     5,993
 
   5,685
 
   5.4
 
          1.6
 
        3.8
                   
Med Devices & Diagnostics
                 
    U.S.
     2,817
 
   2,582
 
   9.1
 
          9.1
 
            -
    International
     3,492
 
   3,060
 
 14.1
 
          4.9
 
        9.2
 
     6,309
 
   5,642
 
 11.8
 
          6.8
 
        5.0
                   
U.S.
     7,867
 
   7,667
 
   2.6
 
          2.6
 
            -
International
     8,684
 
   7,515
 
 15.6
 
          6.4
 
        9.2
Worldwide
 $16,551
 
 15,182
 
   9.0
%
          4.5
 
        4.5
                   
*Fourth Quarter 2009 includes fourteen weeks and 2008 includes thirteen weeks.
   
                   

 
 

 

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
                 
                   
(Unaudited; Dollars in Millions)
TWELVE MONTHS**
         
Percent Change
 
2009
 
2008
 
Total
  Operations
Currency
Sales to customers by
                 
segment of business
                 
                   
Consumer
                 
    U.S.
 $  6,837
 
   6,937
 
   (1.4)
%
         (1.4)
 
            -
    International
     8,966
 
   9,117
 
   (1.7)
 
          4.7
 
       (6.4)
 
   15,803
 
 16,054
 
   (1.6)
 
          2.0
 
       (3.6)
                   
Pharmaceutical
                 
    U.S.
   13,041
 
 14,831
 
 (12.1)
 
       (12.1)
 
            -
    International
     9,479
 
   9,736
 
   (2.6)
 
          3.0
 
       (5.6)
 
   22,520
 
 24,567
 
   (8.3)
 
         (6.1)
 
       (2.2)
                   
Med Devices & Diagnostics
                 
    U.S.
   11,011
 
 10,541
 
    4.5
 
          4.5
 
            -
    International
   12,563
 
 12,585
 
   (0.2)
 
          4.0
 
       (4.2)
 
   23,574
 
 23,126
 
    1.9
 
          4.2
 
       (2.3)
                   
U.S.
   30,889
 
 32,309
 
   (4.4)
 
         (4.4)
 
            -
International
   31,008
 
 31,438
 
   (1.4)
 
          3.9
 
       (5.3)
Worldwide
 $61,897
 
 63,747
 
   (2.9)
%
         (0.3)
 
       (2.6)
                   
**Twelve Months 2009 includes fifty-three weeks and 2008 includes fifty-two weeks.
 

 
 

 

Johnson & Johnson and Subsidiaries
               
Supplementary Sales Data
                 
                   
(Unaudited; Dollars in Millions)
FOURTH QUARTER*
         
Percent Change
 
2009
 
2008
 
Total
  Operations
Currency
Sales to customers by
                 
geographic area
                 
                   
U.S.
 $    7,867
 
     7,667
 
   2.6
%
          2.6
 
            -
                   
Europe
       4,412
 
     3,851
 
 14.6
 
          5.1
 
        9.5
Western Hemisphere excluding U.S.
       1,541
 
     1,187
 
 29.8
 
        19.0
 
      10.8
Asia-Pacific, Africa
       2,731
 
     2,477
 
 10.3
 
          2.3
 
        8.0
International
       8,684
 
     7,515
 
 15.6
 
          6.4
 
        9.2
 
 
 
 
 
 
 
 
 
 
Worldwide
 $  16,551
 
   15,182
 
   9.0
%
          4.5
 
        4.5
                   
*Fourth Quarter 2009 includes fourteen weeks and 2008 includes thirteen weeks.
   
 

 
 

 

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
                 
                   
(Unaudited; Dollars in Millions)
TWELVE MONTHS**
         
Percent Change
 
2009
 
2008
 
Total
  Operations
Currency
Sales to customers by
                 
geographic area
                 
                   
U.S.
 $  30,889
 
   32,309
 
 (4.4)
%
         (4.4)
 
            -
                   
Europe
     15,934
 
   16,782
 
 (5.1)
 
          2.1
 
       (7.2)
Western Hemisphere excluding U.S.
       5,156
 
     5,173
 
 (0.3)
 
          8.8
 
       (9.1)
Asia-Pacific, Africa
       9,918
 
     9,483
 
  4.6
 
          4.4
 
        0.2
International
     31,008
 
   31,438
 
 (1.4)
 
          3.9
 
       (5.3)
 
 
 
 
 
 
 
 
 
 
Worldwide
 $  61,897
 
   63,747
 
 (2.9)
%
         (0.3)
 
       (2.6)
                   
**Twelve Months 2009 includes fifty-three weeks and 2008 includes fifty-two weeks.
 
 


 
 

 

            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
FOURTH QUARTER
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
CONSUMER SEGMENT (2)
           
                   
SKIN CARE
               
US
       
       378
      343
10.2%
10.2%
             -
Intl
       
       572
      501
14.2%
6.7%
7.5%
WW
       
       950
      844
12.6%
8.1%
4.5%
         
 
 
     
BABY CARE
               
US
       
       106
      109
(2.8%)
(2.8%)
             -
Intl
       
       468
      414
13.0%
5.0%
8.0%
WW
       
       574
      523
9.8%
3.4%
6.4%
         
 
 
     
ORAL CARE
               
US
       
       167
      192
(13.0%)
(13.0%)
             -
Intl
       
       241
      204
18.1%
9.1%
9.0%
WW
       
       408
      396
3.0%
(1.7%)
4.7%
         
 
 
     
OTC/NUTRITIONALS
             
US
       
       807
      762
5.9%
5.9%
             -
Intl
       
       767
      694
10.5%
2.2%
8.3%
WW
       
    1,574
   1,456
8.1%
4.2%
3.9%
         
 
 
     
WOMEN'S HEALTH
             
US
       
       135
      148
(8.8%)
(8.8%)
             -
Intl
       
       354
      288
22.9%
12.4%
10.5%
WW
       
       489
      436
12.2%
5.2%
7.0%
         
 
 
     
WOUND CARE / OTHER
           
US
       
       119
      101
17.8%
17.8%
             -
Intl
       
       135
        99
36.4%
20.2%
16.2%
WW
       
       254
      200
27.0%
20.0%
7.0%
         
 
 
     
TOTAL CONSUMER
             
US
       
    1,712
   1,655
3.4%
3.4%
             -
Intl
       
    2,537
   2,200
15.3%
6.5%
8.8%
WW
       
    4,249
   3,855
10.2%
5.2%
5.0%
 
Note: See footnotes at end of schedule
 

 
 

 

            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
    TWELVE MONTHS
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
CONSUMER SEGMENT (2)
           
                 
SKIN CARE
               
US
       
1,582
1,462
8.2%
8.2%
             -
Intl
       
1,885
1,919
(1.8%)
3.9%
(5.7%)
WW
       
3,467
3,381
2.5%
5.7%
(3.2%)
                   
BABY CARE
               
US
       
414
449
(7.8%)
(7.8%)
             -
Intl
       
1,701
1,765
(3.6%)
1.7%
(5.3%)
WW
       
2,115
2,214
(4.5%)
(0.2%)
(4.3%)
                   
ORAL CARE
               
US
       
716
780
(8.2%)
(8.2%)
             -
Intl
       
853
844
1.1%
8.6%
(7.5%)
WW
       
1,569
1,624
(3.4%)
0.5%
(3.9%)
                   
OTC/NUTRITIONALS
             
US
       
2,944
3,061
(3.8%)
(3.8%)
             -
Intl
       
2,686
2,833
(5.2%)
1.9%
(7.1%)
WW
       
5,630
5,894
(4.5%)
(1.1%)
(3.4%)
                   
WOMEN'S HEALTH
             
US
       
578
618
(6.5%)
(6.5%)
             -
Intl
       
1,317
1,293
1.9%
8.4%
(6.5%)
WW
       
1,895
1,911
(0.8%)
3.6%
(4.4%)
                   
WOUND CARE / OTHER
           
US
       
603
567
6.3%
6.3%
             -
Intl
       
524
463
13.2%
19.9%
(6.7%)
WW
       
1,127
1,030
9.4%
12.2%
(2.8%)
                   
TOTAL CONSUMER
             
US
       
6,837
6,937
(1.4%)
(1.4%)
             -
Intl
       
8,966
9,117
(1.7%)
4.7%
(6.4%)
WW
       
15,803
16,054
(1.6%)
2.0%
(3.6%)
 
Note: See footnotes at end of schedule
 

 
 

 
 
 

            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
FOURTH QUARTER
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
PHARMACEUTICAL SEGMENT  (2)
           
                   
ACIPHEX/PARIET
               
US
       
       158
      140
12.9%
12.9%
             -
Intl
       
       154
      134
14.9%
2.7%
12.2%
WW
       
       312
      274
13.9%
8.0%
5.9%
         
 
 
     
CONCERTA
               
US
       
       279
      208
34.1%
34.1%
             -
Intl
       
       102
        72
41.7%
31.2%
10.5%
WW
       
       381
      280
36.1%
33.4%
2.7%
         
 
 
     
DURAGESIC/FENTANYL TRANSDERMAL
           
US
       
         53
        72
(26.4%)
(26.4%)
             -
Intl
       
       180
      200
(10.0%)
(19.4%)
9.4%
WW
       
       233
      272
(14.3%)
(21.2%)
6.9%
         
 
 
     
LEVAQUIN/FLOXIN
               
US
       
       433
      393
10.2%
10.2%
             -
Intl
       
         19
        18
5.6%
1.7%
3.9%
WW
       
       452
      411
10.0%
9.8%
0.2%
         
 
 
     
PROCRIT/EPREX
               
US
       
       308
      318
(3.1%)
(3.1%)
             -
Intl
       
       268
      242
10.7%
(0.3%)
11.0%
WW
       
       576
      560
2.9%
(1.9%)
4.8%
         
 
 
     
RAZADYNE/REMINYL
             
US
       
           6
        11
(45.5%)
(45.5%)
             -
Intl
       
       104
        91
14.3%
2.0%
12.3%
WW
       
       110
      102
7.8%
(3.2%)
11.0%
         
 
 
     
REMICADE
               
US
       
       758
      672
12.8%
12.8%
             -
US Exports (4)
     
       375
      209
79.4%
79.4%
             -
Intl
       
           5
          5
             -
(0.3%)
0.3%
WW
       
    1,138
      886
28.4%
28.4%
             -
 
Note: See footnotes at end of schedule
 
 

 


            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
TWELVE MONTHS
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
PHARMACEUTICAL SEGMENT  (2)
           
                   
ACIPHEX/PARIET
               
US
       
555
539
3.0%
3.0%
             -
Intl
       
541
619
(12.6%)
(6.7%)
(5.9%)
WW
       
1,096
1,158
(5.4%)
(2.3%)
(3.1%)
         
 
 
     
CONCERTA
               
US
       
986
830
18.8%
18.8%
             -
Intl
       
340
417
(18.5%)
(11.9%)
(6.6%)
WW
       
1,326
1,247
6.3%
8.5%
(2.2%)
         
 
 
     
DURAGESIC/FENTANYL TRANSDERMAL
           
US
       
216
271
(20.3%)
(20.3%)
             -
Intl
       
672
765
(12.2%)
(8.3%)
(3.9%)
WW
       
888
1,036
(14.3%)
(11.4%)
(2.9%)
                   
LEVAQUIN/FLOXIN
               
US
       
1,478
1,510
(2.1%)
(2.1%)
             -
Intl
       
72
81
(11.1%)
1.6%
(12.7%)
WW
       
1,550
1,591
(2.6%)
(2.0%)
(0.6%)
         
 
 
     
PROCRIT/EPREX
               
US
       
1,258
1,332
(5.6%)
(5.6%)
             -
Intl
       
987
1,128
(12.5%)
(7.1%)
(5.4%)
WW
       
2,245
2,460
(8.7%)
(6.2%)
(2.5%)
         
 
       
RAZADYNE/REMINYL
             
US
       
36
134
(73.1%)
(73.1%)
             -
Intl
       
379
407
(6.9%)
(0.5%)
(6.4%)
WW
       
415
541
(23.3%)
(18.5%)
(4.8%)
         
 
       
REMICADE
               
US
       
3,088
2,810
9.9%
9.9%
             -
US Exports (4)
     
1,196
927
29.0%
29.0%
             -
Intl
       
20
11
81.8%
78.8%
3.0%
WW
       
4,304
3,748
14.8%
14.8%
             -
 
Note: See footnotes at end of schedule
 
 

 
 


            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
FOURTH QUARTER
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
PHARMACEUTICAL SEGMENT  (2) (Continued)
           
                   
RISPERDAL/RISPERIDONE
           
US
       
         24
        91
(73.6%)
(73.6%)
             -
Intl
       
       169
      194
(12.9%)
(20.9%)
8.0%
WW
       
       193
      285
(32.3%)
(37.8%)
5.5%
         
 
 
     
RISPERDAL CONSTA
             
US
       
       133
      117
13.7%
13.7%
             -
Intl
       
       266
      202
31.7%
20.6%
         11.1
WW
       
       399
      319
25.1%
18.1%
          7.0
         
 
 
     
TOPAMAX
               
US
       
         89
      576
(84.5%)
(84.5%)
             -
Intl
       
       103
      104
(1.0%)
(11.7%)
10.7%
WW
       
       192
      680
(71.8%)
(73.4%)
1.6%
         
 
 
     
VELCADE
               
US
       
          -
         -
             -
                          -
             -
Intl
       
       281
      208
35.1%
26.5%
8.6%
WW
       
       281
      208
35.1%
26.5%
8.6%
         
 
 
     
OTHER
                 
US
       
       722
      623
15.9%
15.9%
             -
Intl
       
    1,004
      785
27.9%
19.1%
8.8%
WW
       
    1,726
   1,408
22.6%
17.7%
4.9%
         
 
 
     
TOTAL PHARMACEUTICAL
           
US
       
    3,338
   3,430
(2.7%)
(2.7%)
             -
Intl
       
    2,655
   2,255
17.7%
8.0%
9.7%
WW
       
    5,993
   5,685
5.4%
1.6%
3.8%
                   
MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
       
                   
PREZISTA
               
US
       
88
50
76.0%
76.0%
             -
Intl
       
91
43
111.6%
98.7%
12.9%
WW
       
179
93
92.5%
86.5%
6.0%
                   
INVEGA
                 
US
       
72
70
2.9%
2.9%
             -
Intl
       
34
25
36.0%
23.8%
12.2%
WW
       
106
95
11.6%
8.4%
3.2%
 
Note: See footnotes at end of schedule
 
 
 

 
 


            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
TWELVE MONTHS
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
PHARMACEUTICAL SEGMENT  (2) (Continued)
           
                   
RISPERDAL/RISPERIDONE
           
US
       
247
1,287
(80.8%)
(80.8%)
             -
Intl
       
652
839
(22.3%)
(21.2%)
(1.1%)
WW
       
899
2,126
(57.7%)
(57.3%)
(0.4%)
         
 
 
     
RISPERDAL CONSTA
             
US
       
519
456
13.8%
13.8%
             -
Intl
       
906
853
6.2%
14.5%
(8.3%)
WW
       
1,425
1,309
8.9%
14.3%
(5.4%)
         
 
 
     
TOPAMAX
               
US
       
731
2,250
(67.5%)
(67.5%)
             -
Intl
       
420
481
(12.7%)
(5.3%)
(7.4%)
WW
       
1,151
2,731
(57.9%)
(56.6%)
(1.3%)
         
 
 
     
VELCADE
               
US
       
             -
4
(100.0%)
(100.0%)
             -
Intl
       
933
783
19.2%
26.7%
(7.5%)
WW
       
933
787
18.6%
26.0%
(7.4%)
         
 
 
     
OTHER
                 
US
       
2,731
2,481
10.1%
10.1%
             -
Intl
       
3,557
3,352
6.1%
11.4%
(5.3%)
WW
       
6,288
5,833
7.8%
10.8%
(3.0%)
         
 
 
     
TOTAL PHARMACEUTICAL
           
US
       
13,041
14,831
(12.1%)
(12.1%)
             -
Intl
       
9,479
9,736
(2.6%)
3.0%
(5.6%)
WW
       
22,520
24,567
(8.3%)
(6.1%)
(2.2%)
         
 
 
     
MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
                   
PREZISTA
               
US
       
303
159
90.6%
90.6%
             -
Intl
       
289
175
65.1%
77.0%
(11.9%)
WW
       
592
334
77.2%
83.4%
(6.2%)
                   
INVEGA
                 
US
       
266
262
1.5%
1.5%
             -
Intl
       
127
64
98.4%
111.7%
(13.3%)
WW
       
393
326
20.6%
23.2%
(2.6%)
 
Note: See footnotes at end of schedule
 
 
 
 

 

            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
FOURTH QUARTER
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
MEDICAL DEVICES AND DIAGNOSTICS  (2) (3)
           
 
CORDIS (6)
               
US
       
       240
      236
1.7%
1.7%
             -
Intl
       
       457
      448
2.0%
(5.8%)
7.8%
WW
       
       697
      684
1.9%
(3.2%)
5.1%
         
 
 
     
DEPUY
                 
US
       
       828
      744
11.3%
11.3%
             -
Intl
       
       645
      546
18.1%
8.3%
9.8%
WW
       
    1,473
   1,290
14.2%
10.1%
4.1%
                   
DIABETES CARE
               
US
       
       313
      275
13.8%
13.8%
             -
Intl
       
       342
      304
12.5%
2.9%
9.6%
WW
       
       655
      579
13.1%
8.0%
5.1%
         
 
 
     
ETHICON
               
US
       
       458
      363
26.2%
26.2%
             -
Intl
       
       651
      555
17.3%
7.5%
9.8%
WW
       
    1,109
      918
20.8%
14.8%
6.0%
         
 
 
     
ETHICON ENDO-SURGERY
           
US
       
       532
      515
3.3%
3.3%
             -
Intl
       
       724
      602
20.3%
10.5%
9.8%
WW
       
    1,256
   1,117
12.4%
7.0%
5.4%
         
 
 
     
ORTHO-CLINICAL DIAGNOSTICS
           
US
       
       258
      248
4.0%
4.0%
             -
Intl
       
       243
      204
19.1%
10.6%
8.5%
WW
       
       501
      452
10.8%
6.9%
3.9%
         
 
 
     
VISION CARE
               
US
       
       188
      201
(6.5%)
(6.5%)
             -
Intl
       
       430
      401
7.2%
(0.7%)
7.9%
WW
       
       618
      602
2.7%
(2.6%)
5.3%
         
 
 
     
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
         
US
       
    2,817
   2,582
9.1%
9.1%
             -
Intl
       
    3,492
   3,060
14.1%
4.9%
9.2%
WW
       
    6,309
   5,642
11.8%
6.8%
5.0%
 
Note: See footnotes at end of schedule
 
 
 

 

            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
TWELVE MONTHS
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
MEDICAL DEVICES AND DIAGNOSTICS  (2) (3)
           
 
CORDIS (6)
               
US
       
971
1,165
(16.7%)
(16.7%)
             -
Intl
       
1,708
1,823
(6.3%)
(4.4%)
(1.9%)
WW
       
2,679
2,988
(10.3%)
(9.1%)
(1.2%)
                   
DEPUY
                 
US
       
3,096
2,873
7.8%
7.8%
             -
Intl
       
2,276
2,263
0.6%
7.2%
(6.6%)
WW
       
5,372
5,136
4.6%
7.5%
(2.9%)
                   
DIABETES CARE
               
US
       
1,221
1,265
(3.5%)
(3.5%)
             -
Intl
       
1,219
1,270
(4.0%)
0.8%
(4.8%)
WW
       
2,440
2,535
(3.7%)
(1.3%)
(2.4%)
                   
ETHICON
               
US
       
1,754
1,450
21.0%
21.0%
             -
Intl
       
2,368
2,390
(0.9%)
4.5%
(5.4%)
WW
       
4,122
3,840
7.3%
10.7%
(3.4%)
                   
ETHICON ENDO-SURGERY
           
US
       
1,974
1,901
3.8%
3.8%
             -
Intl
       
2,518
2,385
5.6%
10.6%
(5.0%)
WW
       
4,492
4,286
4.8%
7.6%
(2.8%)
                   
ORTHO-CLINICAL DIAGNOSTICS
           
US
       
1,104
997
10.7%
10.7%
             -
Intl
       
859
844
1.8%
6.3%
(4.5%)
WW
       
1,963
1,841
6.6%
8.6%
(2.0%)
                   
VISION CARE
               
US
       
891
890
0.1%
0.1%
             -
Intl
       
1,615
1,610
0.3%
                      -
0.3%
WW
       
2,506
2,500
0.2%
0.1%
0.1%
                   
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
         
US
       
11,011
10,541
4.5%
4.5%
             -
Intl
       
12,563
12,585
(0.2%)
4.0%
(4.2%)
WW
       
23,574
23,126
1.9%
4.2%
(2.3%)
 
(1) Operational growth excludes the effect of currency.
(2) Select areas (unaudited).
(3) Prior year amounts have been reclassified to conform with current presentation.
(4) Reported in U.S. sales.
(5) Included in Other.
(6) Includes sales of Drug-Eluting Stents for Q4 2009 of $56, $167 and $223MM Domestic, International and Worldwide, respectively.
      Includes sales of Drug-Eluting Stents for Q4 2008 of $70, $202 and $272MM Domestic, International and Worldwide, respectively.
      Includes sales of Drug-Eluting Stents for December YTD 2009 of $245, $674 and $919MM Domestic, International and Worldwide,
        respectively.
      Includes sales of Drug-Eluting Stents for December YTD 2008 of $503, $852 and $1,355MM Domestic, International and Worldwide,
        respectively.